SWOT Analysis for Jubilant Pharmova Ltd. - Weakness

Add SWOT widget to your site/app

Benjamin Graham Value Screen

Mid-range Performer (DVM)

Growth Stars: Strongest Annual EPS Performers

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Companies with Low Debt

Companies with reducing Debt

Increasing Revenue every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Top Gainers

Companies with growing costs YoY for long term projects

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Major fall in TTM Net Profit

Weak Momentum: Price below Short, Medium and Long Term Averages

Increasing Trend in Non-Core Income

RSI indicating price weakness

High promoter stock pledges

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Broker downgrades in price or recommendation in the past one month

Red Flags: Weakening Technicals and Share Price Decline

High Piotroski Score - Companies with strong financials

Stocks with improving cash flow, with good durability

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)